Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?

Clinical Nuclear Medicine

Volumn 37, Issue 6, 2012, Pages

  Ezziddin, Samer ^a   Lohmar, Jonas ^a   Yong Hing, Charlotte J ^b   Sabet, Amir ^a   Ahmadzadehfar, Hojjat ^a   Kukuk, Guido ^a   Biersack, Hans Jürgen ^a   Guhlke, Stefan ^a   Reichmann, Karl ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

68Ga DOTATOC PET CT; dosimetry; gastroenteropancreatic neuroendocrine tumors; Lu 177 DOTA octreotate; peptide receptor radionuclide therapy

Indexed keywords

CHROMOGRANIN A; GALLIUM 68 TETRAXETAN TYROSINE OCTREOTIDE; KI 67 ANTIGEN; LUTETIUM 177; OCTREOTIDE; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DOSIMETRY; FEMALE; HUMAN; LIVER METASTASIS; MALE; PANCREAS; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PREDICTION; RADIATION DOSE; RADIOISOTOPE THERAPY; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; TUMOR LOCALIZATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; HUMANS; INTESTINAL NEOPLASMS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84861447519     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31823926e5     Document Type: Article

References (29)

1. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptorbased imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
2. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog E177 Lu-DOTA 0,Tyr3octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
3. Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue E177Lu-DOTA(0),Tyr3octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422. (Pubitemid 36692868)
4. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010;54:37-51.
5. Wehrmann C, Senftleben S, Zachert C, et al. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTATATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22: 406-416. (Pubitemid 47067899)
6. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog E177Lu-DOTA0,Tyr3octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762. (Pubitemid 46179465)
7. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220-226.
8. Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1):172S-178S.
9. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/ CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTATOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004-2010.
10. Koukouraki S, Strauss LG, Georgoulias V, et al. Evaluation of the pharmacokinetics of 68Ga DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:460-466.
11. Versari A, Camellini L, Carlinfante G, et al. 68Ga DOTATOC PET, endoscopic ultrasonography and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin Nucl Med. 2010;35:321-328.
12. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(suppl 1):11SY20S.
13. Breeman WA, De Jong M, Visser TJ, et al. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917-920. (Pubitemid 36734213)
14. Boy C, Heusner TA, Poeppel TD, et al. 68Ga DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUV(max). Eur J Nucl Med Mol Imaging. 2011;38:1224-1236.
15. Luboldt W, Hartmann H, Wiedemann B, et al. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy. Mol Imaging. 2010;9:351-358.
16. Vilar E, Salazar R, Perez-Garcia J, et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14:221-232. (Pubitemid 47242624)
17. Pape UF, Berndt U, Muller-Nordhorn J, et al. Prognostic factors of longterm outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2008;15:1083-1097.
18. Kloppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009; 90:162-166.
19. Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:459-466.
20. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273-282. (Pubitemid 30167697)
21. Mussig K, Oksuz MO, Dudziak K, et al. Association of somatostatin receptor 2 immunohistochemical expression with E111In-DTPA octreotide scintigraphy and 68Ga DOTATOC PET/CT in neuroendocrine tumors. Horm Metab Res. 2010;42:599-606.
22. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007;20:1172-1182. (Pubitemid 47609066)
23. Miederer M, Seidl S, Buck A, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga DOTATOC PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:48-52.
24. Belhocine T, Foidart J, Rigo P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun. 2002;23:727-734. (Pubitemid 34837002)
25. Ezziddin S, Logvinski T, Yong-Hing C, et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2006;47: 223-233. (Pubitemid 46780886)
26. Forrer F, Uusijarvi H, Waldherr C, et al. A comparison of (111)In- DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1257-1262. (Pubitemid 39222489)
27. Esser JP, Krenning EP, Teunissen JJ, et al. Comparison of E(177)Lu- DOTA(0),Tyr(3)octreotate and E(177)Lu-DOTA(0),Tyr(3)octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging. 2006;33: 1346-1351. (Pubitemid 44630791)
28. Wieder H, Beer AJ, Poethko T, et al. PET/CTwith Gluc-Lys-(E(18)FFP)- TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions. Eur J Nucl Med Mol Imaging. 2008;35: 264-271.
29. Garkavij M, Nickel M, Sjogreen-Gleisner K, et al. 177Lu-EDOTA0,Tyr3 octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116:1084-1092.